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Hepatitis C virus (HCV) is a positive-strand RNA virus that frequently causes persistent infections and is uniquely
associated with the development of hepatocellular carcinoma. While the mechanism(s) by which the virus promotes
cancer are poorly defined, previous studies indicate that the HCV RNA-dependent RNA polymerase, nonstructural
protein 5B (NS5B), forms a complex with the retinoblastoma tumor suppressor protein (pRb), targeting it for
degradation, activating E2F-responsive promoters, and stimulating cellular proliferation. Here, we describe the
mechanism underlying pRb regulation by HCV and its relevance to HCV infection. We show that the abundance of pRb
is strongly downregulated, and its normal nuclear localization altered to include a major cytoplasmic component,
following infection of cultured hepatoma cells with either genotype 1a or 2a HCV. We further demonstrate that this is
due to NS5B-dependent ubiquitination of pRb and its subsequent degradation via the proteasome. The NS5B-
dependent ubiquitination of pRb requires the ubiquitin ligase activity of E6-associated protein (E6AP), as pRb
abundance was restored by siRNA knockdown of E6AP or overexpression of a dominant-negative E6AP mutant in cells
containing HCV RNA replicons. E6AP also forms a complex with pRb in an NS5B-dependent manner. These findings
suggest a novel mechanism for the regulation of pRb in which the HCV NS5B protein traps pRb in the cytoplasm, and
subsequently recruits E6AP to this complex in a process that leads to the ubiquitination of pRb. The disruption of pRb/
E2F regulatory pathways in cells infected with HCV is likely to promote hepatocellular proliferation and chromosomal
instability, factors important for the development of liver cancer.
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Introduction
Among viruses that infect the human liver, hepatitis C virus
(HCV) is a leading cause of morbidity and mortality world-
wide [1]. Chronic infection with HCV is a major risk factor
for the development of cirrhosis as well as hepatocellular
carcinoma (HCC) [2,3]. The incidence of this cancer has
increased dramatically in recent years in Japan and the
United States, reﬂecting prior increases in the prevalence of
HCV infection, and in Japan HCV has replaced hepatitis B
virus as the leading infectious cause of liver cancer. The
strong association between HCC and HCV infection is
particularly notable in that HCV is a positive-strand RNA
virus, classiﬁed within the genus Hepacivirus of the family
Flaviviridae [4]. Its 9.6-kb genome replicates in association
with membranes within the cytoplasm of infected cells, and
encodes a single polyprotein that is processed by both cellular
and viral proteases into ten individual structural and
nonstructural viral proteins.
Although inﬂammation associated with chronic hepatitis
C is likely to contribute to the development of HCC, there is
strong evidence that one or more of the proteins expressed
by the virus contribute directly to carcinogenesis. The HCV
core protein, a component of the putative viral nucleocap-
sid, has been shown to modulate the hepatocyte cell cycle
[5,6]. Other studies suggest that expression of the non-
structural (NS) proteins, NS3 (a serine proteinase/helicase),
NS5A (a replicase-associated phosphoprotein of uncertain
function), or NS5B (the viral RNA-dependent RNA polymer-
ase) may also affect control of cellular proliferation [7–10].
Moreover, transgenic mice expressing a high abundance of
the core protein develop steatosis and HCC [11]. Liver
cancer also developed in transgenic mice expressing a much
lower abundance of the entire viral polyprotein, but not in
a companion transgenic lineage expressing a higher
abundance of the structural proteins (core, E1, E2, and p7)
only [12]. None of these transgenic mouse lineages had
demonstrable hepatic inﬂammation in advance of the
development of HCC. Together, these data suggest a direct
role for both structural and nonstructural HCV proteins in
oncogenesis.
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proliferation or cell death, the retinoblastoma (pRb)/E2F,
p53, transforming growth factor-b (TGF-b), and b-catenin
pathways, are commonly altered in HCCs [2]. Among them,
pRb plays a major role in controlling the G1- to S-phase
transition and mitotic checkpoints through a repressive
effect on E2F transcription factors [13]. pRb functions as a
tumor suppressor, and the gene which encodes it (RB)i s
frequently mutated in various types of tumors, including
retinoblastomas, small-cell lung carcinomas, and osteosarco-
mas [14]. In previously published studies, we demonstrated
that pRb protein abundance is negatively regulated in cells
supporting the replication of subgenomic and genome-
length HCV RNA replicons [8]. Similar to the DNA virus
oncoproteins E1A of adenovirus and E7 of human papil-
lomavirus (HPV), we found that the RNA-dependent RNA
polymerase of HCV, NS5B, forms a complex with pRb in
these cells, targeting pRb for degradation and resulting in a
reduction in its abundance. This leads to the activation of
E2F-responsive promoters in cells containing HCV RNA
replicons, and promotes progression of the cell cycle from
G1- to S-phase in cells expressing NS5B [8]. While
potentially important with respect to the development of
HCC in people with chronic hepatitis C, the molecular
mechanisms underlying these observations have not been
characterized.
Here, we show that pRb is downregulated not only in cells
bearing HCV RNA replicons, but also in human hepatoma
cells infected in vitro with different genotypes of HCV. We
demonstrate that the downregulation of pRb occurs via the
ubiquitin-proteasome system, and that it is dependent upon
the activity of a known E3 ubiquitin ligase, E6-associated
protein (E6AP). E6AP forms a complex with NS5B and pRb,
and pRb is ubiquitinated in an NS5B-dependent manner. Our
ﬁndings reveal a novel mechanism that regulates pRb
abundance in HCV-infected hepatocytes, and offer an
enhanced understanding of the events leading to the
development of HCC in chronically infected patients.
Results
HCV Infection Downregulates pRb and Phospho-pRb
Expression In Vitro
We demonstrated previously that the abundance of pRb is
downregulated post-transcriptionally in cells supporting
replication of both subgenomic and genome-length HCV
RNA replicons derived from a genotype 1b strain of HCV,
HCV-N [8]. However, these earlier studies did not determine
whether pRb is also downregulated during the course of HCV
infection, because genome-length HCV-N RNA is not capable
of producing virus that is infectious in cultured cells [15]. To
address this question, we used a genotype 2a virus strain,
JFH1, that is capable of undergoing the complete viral life
cycle in Huh-7 cells in vitro [16–18]. pRb abundance was
reduced signiﬁcantly within 48–72 h of infection with JFH1
virus (Figure 1A and 1B), with quantitative analysis of
immunoblots indicating that the pRb abundance 120 h after
infection was approximately 20%–30% that of uninfected
cells (Figures 1C and S1). The activity of pRb is normally
regulated through its phosphorylation by cyclin-dependent
kinases, and we also observed an equivalent reduction in the
abundance of phospho-pRb in JFH1-infected cells using an
antibody speciﬁc for pRb phosphorylated at residues 807/811
(Figure 1D and 1E).
Coincident with the reduction in total pRb abundance,
confocal microscopy demonstrated a striking cytoplasmic
relocalization of pRb in JFH1-infected cells (Figure 2A). Our
earlier studies demonstrated that expression of the NS5B
RNA polymerase is responsible for the downregulation of
pRb in replicon-bearing cells, and that NS5B interacts
directly with pRb through a Leu-X-Cys-X-Glu homology
domain (LH
314–318) overlapping the polymerase active site [8].
Since we lack antibody capable of labeling the genotype 2a
NS5B protein within infected cells, we labeled the viral
replicase complex in these cells with a broadly reactive
polyclonal antibody to NS5A. NS5A is known to colocalize
with HCV RNA and other HCV nonstructural proteins within
the cytoplasmic ‘‘membranous webs’’ that are thought to be
sites of viral RNA synthesis [19]. These studies revealed
numerous JFH1-infected cells with an abnormal cytoplasmic
accumulation of pRb, and a clear colocalization with the HCV
replicase complex as labeled with anti-NS5A (Figure 2A,
frame iv). Although the sensitivity of confocal microscopy for
detection of pRb renders it difﬁcult to deduce quantitative
differences in nuclear pRb abundance in infected versus
noninfected cells, we noted similar cytoplasmic relocalization
of pRb in cells infected with a cell culture–infectious
genotype 1a virus (H77S) developed recently in our labo-
ratory [20] (Figure 2B). Some H77S-infected cells demon-
strated nearly complete relocalization of pRb to the
cytoplasm (Figure 2B, frame ii arrow), while in most infected
cells, there was partial cytoplasmic relocalization (Figure 2B,
frame iv arrow). A quantitative analysis of multiple cells
indicated that there was a signiﬁcant increase in the
proportion of total pRb present in the cytoplasm of infected
versus noninfected cells (Figure 2C; p , 0.001). Confocal
microscopy also conﬁrmed a striking reduction in nuclear
phospho-pRb in JFH1-infected cells (Figure 2D; compare
frames i and iii). Phospho-pRb was found to accumulate
within the cytoplasm following treatment with epoxomicin
(Figure 2D, frame vi). These results are consistent with an
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Author Summary
Persons infected with hepatitis C virus (HCV) are at increased risk for
liver cancer. This is remarkable because HCV is an RNA virus with
replication confined to the cytoplasm and no potential for
integration of its genome into host cell DNA. While it is likely that
chronic inflammation contributes to liver cancer, prior studies with
HCV transgenic mice indicate that the viral proteins are intrinsically
carcinogenic. In this study, we have examined the interaction of one
of these, the RNA-dependent RNA polymerase nonstructural protein
5B, with an important cellular tumor suppressor protein, the
retinoblastoma protein (pRb). pRb is a master regulator of the cell
cycle, and altered expression of some of the many genes it regulates
may lead to cancer. We show that the abundance of pRb is strongly
downregulated in cells infected with HCV, and that nonstructural
protein 5B targets pRb for destruction via the cell’s normal protein
degradation machinery. The E6-associated protein appears to play a
role in this process, which is interesting as it also mediates the
degradation of another tumor suppressor, p53, by papillomaviruses.
The loss of pRb function in HCV-infected cells likely promotes
hepatocellular proliferation as well chromosomal instability, factors
important for the development of liver cancer.interaction occurring between NS5B and pRb within the
cytoplasm. While pRb is normally conﬁned to the nucleus, it
does undergo nuclear-cytoplasmic shuttling involving phos-
phorylation-dependent nuclear export mediated by expor-
tin1 [21]. It is likely that NS5B interacts with and traps pRb in
the cytoplasm prior to its initial transport to the nucleus, or
perhaps after nuclear export.
HCV Promotes Proteasome-Dependent Degradation of
pRb
Although our previous studies demonstrated that NS5B
downregulates the abundance of pRb post-transcriptionally
[8], the mechanism by which this occurs is not clear. We
conﬁrmed our earlier observations that the stability of pRb is
reduced in cells supporting HCV RNA replication by carrying
out additional pulse-chase labeling experiments in Huh-7 2–3
cells which contain a genome-length RNA replicon [22].
These results indicated a signiﬁcantly shortened half-life for
pRb in the replicon cells, compared with clonally related cells
(2–3c cells) from which the HCV RNA had been eliminated by
prior interferon treatment (Figure 3A).
Since the abundance of pRb is regulated through protea-
some-dependent pathways in the absence of HCV protein
expression [23,24], we considered it likely that HCV may also
regulate pRb in a proteasome-dependent fashion. To test this
hypothesis, we determined whether proteasome inhibitors
[25,26] could restore the abundance of pRb in 2–3 replicon
cells. As shown in Figure 3B, epoxomicin, a potent and
selective synthetic inhibitor of multiple protease activities of
the proteasome, caused a marked increase in pRb abundance,
nearly to normal levels, in 2–3 cells (Figure 3B, top panels). In
contrast, epoxomicin treatment caused a slight increase in
pRb abundance in the cured, HCV-negative 2–3c cell line
(Figure 3B, lower panels), consistent with the normal
regulation of pRb abundance by proteasomal degradation
[23,24]. We also observed similar, cell-type–speciﬁc restora-
tion of pRb abundance in 2–3 cells after treatment with
lactacystin, an irreversible inhibitor of the 20S proteasome,
or MG115, a reversible inhibitor of 20S and 26S proteasomes
(Figure S2). Immunoﬂuorescence analysis conﬁrmed the
rescue of pRb expression following MG115 treatment of 2–3
replicon cells, but revealed that pRb was localized primarily
within the cytoplasm, and not the nucleus, in most 2–3 cells
following treatment with the proteasome inhibitor (Figure
3C, arrows). Importantly, pRb retained its normal nuclear
localization in MG115-treated 2–3c cells that lack HCV
protein expression (Figure 3C, bottom panels). The retention
of pRb in the cytoplasm of MG115-treated replicon cells
(Figure 3C) is consistent with the interaction of NS5B
discussed above. This interaction appears to trap the tumor
suppressor protein within the cytoplasm and prevent its
translocation to the nucleus in advance of its degradation by
the proteasome.
To determine whether inhibition of the proteasome would
similarly rescue pRb expression in cells infected with HCV,
we treated JFH1-infected cells with epoxomicin. As shown in
Figure 3D, this resulted in a marked increase in the
abundance of pRb (compare lanes 1 versus 2), as well as an
increase in high-molecular-mass pRb-immunoreactive pro-
tein. While the identity of this high-mass pRb-immunor-
Figure 1. Infection of Cultured Human Hepatoma (Huh-7.5) Cells Leads to Downregulation of pRb Abundance
(A) Schema for experiment shown in (B–E). Huh-7.5 cells were seeded into culture vessels and infected with JFH1 virus (MOI ;1) at intervals, and
subsequently lysed simultaneously for immunoblot analysis. Solid bars show infected; shaded bars, uninfected.
(B) Immunoblots for total pRb and NS5B in cells infected with JFH1 virus according to the protocol outlined in (A). GAPDH was used as a loading control.
(C) Mean 6 range of values for abundance of pRb in cells infected with JFH1 virus in replicate experiments, relative to abundance in uninfected cells.
(D) Immunoblots for phospho-pRb (residues 807/811) and NS5B in cells infected with JFH1 virus. GAPDH was used as a loading control. Lanes 6–7
demonstrate the specificity of the phospho-pRb: lysate from uninfected Huh-7.5 cells was subjected to immunoblotting before (lane 6) and after (lane
7) digestion with lambda protein phosphatase (k-PPase).
(E) Mean 6 range of values for abundance of phospho-pRb (residues 807/811) in cells infected with JFH1 virus in replicate experiments, relative to
abundance in uninfected cells.
doi:10.1371/journal.ppat.0030139.g001
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ubiquitinated pRb (see below). The abundance of phospho-
pRb was also increased following epoxomicin treatment of
JFH1-infected cells, although there we observed no discern-
able high-molecular-mass phospho-pRb species (Figure 3D,
lanes 3 versus 4). Considered collectively, these results
indicate that HCV regulates the abundance of pRb by
promoting its proteasome-dependent degradation. Although
overexpression studies have suggested that the NS5B
polymerase itself may be regulated by polyubiquitination
and proteasome-mediated degradation [27], epoxomicin
treatment did not enhance, but rather reduced, the
abundance of NS5B in both HCV-infected and replicon
cells (Figures 3B and 3D).
Figure 2. Confocal Microscopic Images Demonstrated Alterations in pRb and Phospho-pRb Expression Associated with HCV Infection of Huh-7.5
Human Hepatoma Cells
(A) pRb accumulates in the cytoplasm of cells 48 h after infection with genotype 2a JFH1 virus. Cells were labeled with polyclonal antibody to the HCV
NS5A protein (Alexa-594; red) and monoclonal anti-pRb (fluorescein; green), and counterstained with DAPI (blue) to visualize nuclei. Two cells near the
center of the field are infected with virus and show cytoplasmic displacement of pRb. Frames: i, DAPI only; ii, pRb; iii, NS5A; iv, merge.
(B) Confocal microscopic images of Huh-7.5 cells 84 h after infection with the genotype 1a H77S virus [20] at low MOI. Labeling of HCV antigens with
polyclonal human antibody (fluorescein; green) revealed both infected and uninfected cells. pRb was labeled with monoclonal antibody (Alexa-568;
red), and in infected cells has been either partially (frame iv, arrow) or completely (frame ii, arrow) redirected to the cytoplasm. Nuclei were visualized by
DAPI staining. Frames: i, DAPI only; ii, pRb; iii, HCV; iv, merge.
(C) The cytoplasmic and nuclear abundance of pRb was determined quantitatively in confocal microscopic images of H77S virus–infected Huh-7.5 cells
using MetaMorph software (Molecular Devices, http://www.moleculardevices.com/). The average integrated intensities of the pRb fluorescence signal
were determined for both the cytoplasm and nucleus (delineated by DAPI staining) in individual infected and immediately adjacent uninfected cells.
These data were used to calculate a cytoplasmic–nuclear pRb ratio for each individual cell. Infected cells (identified by labeling of HCV antigens as in [A])
and uninfected cells were analyzed separately, revealing a striking difference in the ratio of cytoplasmic–nuclear pRb staining intensity in infected (0.65)
versus uninfected (0.17) cells (p , 0.001 by Student t test).
(D) Confocal microscopy images of phospho-pRb expression in uninfected Huh-7.5 cells (frames i and ii), and 96 h following infection with the genotype
2a JFH1 virus (frames iii–vi). Frames i, iii, and v show labeling with monoclonal antibody to phospho-pRb 807/811 (red) only, whereas frames ii, iv, andv i
show merged images of phospho-pRb (red), HCV (human polyclonal antibody; green), and DAPI labeling. The red channel gain was increased in frames
iii–vi in order to normalize the intensity of phospho-pRb labeling within the nuclei of noninfected cells with that in frames i and ii. Nuclear phospho-pRb
expression was ablated by JFH1 infection, and only partially restored after 20 h of treatment with 50 nM epoxomicin (frames v and vi). The arrow in
frame vi indicates an accumulation of phospho-pRb within the cytoplasm of an infected cell following epoxomicin treatment.
doi:10.1371/journal.ppat.0030139.g002
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Although pRb abundance is normally regulated through
proteasome-dependent pathways, such regulation does not
necessarily require the ubiquitination of pRb [23,24]. The
increase we observed in the abundance of high-molecular-
mass pRb-immunoreactive protein in lysates of JFH1-infected
hepatoma cells prepared following treatment with epoxomi-
cin (Figure 3D, lane 2) suggests that HCV infection might
promote the polyubiquitination of pRb. To assess this
possibility, we immunoprecipitated pRb from lysates of
Huh-7.5 cells that were infected with the JFH1 virus, then
analyzed the precipitates in immunoblots using antibody to
ubiquitin. We similarly studied infected cells that had been
treated with epoxomicin for 20 h prior to lysis. These results
revealed that HCV infection induces polyubiquitination of
pRb (Figure 4A, lane 1). A signiﬁcant abundance of
polyubiquitinated pRb was not detected in lysates from
mock-infected cells, even following treatment with epoxomi-
cin (Figure 4A, compare lanes 3 and 1).
We also demonstrated HCV-dependent polyubiquitination
of pRb in the 2–3 replicon cells by transfecting the cells with a
vector expressing Flag-tagged ubiquitin, followed by immu-
noprecipitation (IP) of lysates with anti-Flag antibody and
immunoblotting with anti-pRb (Figure 4B). While a small
amount of polyubiquitinated pRb was detected in lysates of
the cured 2–3c cells following treatment with MG115 (Figure
4B, lane 6), this was readily detected in lysates of untreated 2–
3 replicon cells, and increased by MG115 treatment (Figure
4B, lanes 7–8). We obtained similar results in cells treated
with lactacystin (unpublished data). Importantly, the anti-Flag
precipitates from the 2–3 cells also contained abundant
NS5B, indicating that NS5B was associated with the ubiquiti-
Figure 3. HCV Promotes Proteasome-Mediated Degradation of pRb
(A) Pulse-chase labeling of pRb in 2–3 replicon (squares) and cured 2–3c (circles) cells. Cells were pulse labeled with [
35S]-methionine/cysteine for 30
min, then chased with DMEM supplemented with cysteine and methionine and lysed at the times indicated. pRb was immunoprecipitated from lysates
and separated by SDS-PAGE. [
35S] was quantified by PhosphoImager analysis. Results represent the mean 6 range % [
35S] label recovered from each
cell type at 0 h.
(B) Inhibition of the proteasome with epoxomicin (EPX) partially restores pRb abundance in NNeo-C5B/2–3 cells containing an autonomously
replicating, genome-length HCV RNA replicon. 2–3 cells and their interferon-cured, HCV-negative progeny, 2–3c cells [58], were treated with 0, 50, or
500 nM EPX for 20 h, followed by lysis and immunoblot analysis of pRb and NS5B. GAPDH was used as a loading control.
(C) Inhibition of the proteasome with MG115 increases cytoplasmic pRb abundance in 2–3 replicon cells. 2–3 (top and middle frames) and 2–3c (lower
frames) cells were treated with 0 lM (top frames) or 20 lM (middle and lower frames) MG115 for 8 h prior to fixation, labeling with anti-pRb and DAPI,
and examination with a fluorescence microscope. Frames on the left show pRb labeling (fluorescein; green), while frames on the right show merged
pRb and nuclear (DAPI; blue) labeling. Arrows denote MG115-treated 2–3 cells in which pRb expression is entirely cytoplasmic, with no apparent nuclear
staining.
(D) EPX treatment restores (lanes 1–2) pRb and (lanes 3–4) phospho-pRb abundance, and increases the abundance of high-molecular-mass pRb-
immunoreactive protein (probable polyubiquitinated pRb) in HCV-infected cells. Cells were infected for 96 h with JFH1 virus and treated with 250 nM
EPX for 20 h prior to lysis and immunoblot analysis.
doi:10.1371/journal.ppat.0030139.g003
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no high-molecular-mass forms of NS5B, suggesting that there
is no appreciable ubiquitination of NS5B under these
conditions. These results conﬁrm that HCV infection and/or
RNA replication induce polyubiquitination of pRb as a
prelude to its degradation by the proteasome.
Since our prior studies revealed that NS5B binds to and
induces the degradation of pRb [8], we asked whether ectopic
expression of NS5B would also induce pRb ubiquitination.
We transfected normal Huh-7 cells with vectors expressing
Flag-tagged HCV nonstructural proteins (NS3-4A, NS4B,
NS5A, and NS5B), and immunoprecipitated cell extracts with
anti-pRb, followed by immunoblotting with anti-ubiquitin
antibodies. Overexpression of Flag-NS5B, but not other HCV
nonstructural proteins, reproducibly resulted in polyubiqui-
tination of pRb (Figure 4C). In contrast, the ectopic
expression of an NS5B mutant (D318N/D319N) containing
substitutions within the LH
314–318 domain that mediates the
interaction of NS5B with pRb [8] resulted in only minimal
ubiquitination of pRb (Figure 4C; compare lanes 5 and 6).
These data indicate that the interaction of NS5B with pRb
leads to targeted destruction of pRb via the ubiquitin-
proteasome pathway, representing a striking parallel to the
mechanism by which the HPV E6 protein mediates destruc-
tion of p53 [28].
HCV-Induced Degradation of pRb Is Dependent upon
E6AP
A PROSITE (http://ca.expasy.org/prosite/) search indicated
that the NS5B protein does not contain a RING ﬁnger, or a
HECT or ubiquitin interaction motif, making it unlikely that
NS5B itself possesses ubiquitin ligase activity [29]. Thus, NS5B
is more likely to induce the ubiquitination of pRb by
mediating its interaction with a cellular ubiquitin ligase. In
searching for this protein, we focused on two recognized
cellular E3 ubiquitin ligases: the human homolog of the
murine ‘‘double minute 2’’ protein (MDM2), which is involved
in ubiquitination pathways that normally regulate the
abundance of pRb and p53 [23,24,30], and E6-associated
protein (E6AP) which is recruited by the HPV E6 protein to
Figure 4. HCV Infection and RNA Replication Induces Polyubiquitination of pRb
(A) Polyubiquitination of pRb in HCV-infected hepatoma cells. Huh-7.5 cells were infected with JFH1 virus (þ) or mock-infected ( ) for 96 h, and treated
(þ) or not treated ( ) with EPX (250 nM) for 20 h prior to lysis, precipitation with anti-pRb, and immunoblotting with either anti-ubiquitin (Ubi; top
panel) or anti-pRb antibody (bottom panels).
(B) Polyubiquitination of pRb in HCV replicon cells. 2–3 and 2–3c cells were transfected with a Flag-ubiquitin expression vector and cultured in the
presence or absence of MG115 prior to preparation of lysates. Lysates were immunoprecipitated with anti-Flag antibody, followed by immunoblotting
with anti-pRb (top panel) or anti-NS5B (middle panel). The lower panel shows direct NS5B immunoblotting of the cell lysates. Ubiquitination of
endogenous pRb is evident in the replicon cells even in the absence of MG115 treatment. NS5B is associated with the ubiquitinated Rb.
(C) Ectopic expression of wild-type (wt) NS5B induces polyubiquitination of pRb in normal Huh-7 cells. Cells were transfected with vectors expressing
Flag-tagged NS3-4A, NS4B, NS5A, NS5B, and a mutant NS5B, D318N/D319N, then treated with MG115. Cell extracts were immunoprecipitated with anti-
pRb, followed by immunoblotting with anti-ubiquitin (top panel). The bottom panels show immunoblots of the cell extracts carried out with antibodies
to pRb, Flag (expression control), and actin (loading control).
doi:10.1371/journal.ppat.0030139.g004
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also known to form a complex with ubiquilin-1 (hPLIC-1), a
ubiquitin-like protein that has been shown to interact with
NS5B [27,31]. Also, recent studies indicate that E6AP
mediates the ubiquitination and degradation of the HCV
core protein [32].
To assess the role of these two ubiquitin ligases in NS5B-
mediated degradation of pRb, we used siRNA interference to
examine the impact of MDM2 and E6AP knockdown on pRb
abundance in the 2–3 replicon cells. Using pools consisting of
four different speciﬁc siRNAs, we were able to achieve
effective reductions of each targeted protein (Figure 5A).
MDM2 knockdown resulted in a modest but variable increase
in pRb abundance (Figure 5A; compare lane 8 with lanes 1
and 2), while knockdown of E6AP reproducibly restored pRb
abundance to a level approaching that of the control 2–3c
cells (Figure 5A; compare lane 9 with lanes 1 and 2). Two
different control siRNAs failed to increase pRb abundance in
the replicon cells (lanes 6 and 7). This was also the case with
an siRNA pool speciﬁc for an E3 ligase sharing the C-terminal
HECT domain of E6AP, neural precursor cell–expressed
developmentally downregulated protein 4 (NEDD4) (lane 8)
[33], indicating that the effect of E6AP knockdown was
speciﬁc to that protein. None of the siRNAs tested signiﬁ-
cantly enhanced the abundance of pRb in the control, HCV-
negative cells (Figure 5A, lanes 1–5).
To further assess the speciﬁcity of the E6AP knockdown, we
transfected 2–3 and 2–3c cells with each of the four individual
siRNA molecules present in the E6AP pool tested in Figure
5A. These results demonstrated robust enhancement of pRb
abundance in cells transfected with three of the E6AP-speciﬁc
siRNAs (E5, E6, and E7), while none of the siRNAs inﬂuenced
pRb abundance in the control 2–3c cells (Figure 5B).
Transfection of siRNA E8 reduced the abundance of E6AP,
but had no apparent effect on pRb abundance (Figure 5B,
lane 10). It is possible that this might reﬂect the involvement
of an E6AP splicing variant, as the E5, E6, and E7 siRNAs all
target exon 9 of the E6AP gene, while E8 targets exon 10 [34].
Alternatively, we observed kinetic differences in the rates of
pRb restoration with these siRNAs, most likely reﬂecting
different efﬁciencies of E6AP knockdown (unpublished data).
Transfection of siRNAs E5 and E6 resulted in increased pRb
abundance within 48 h, while this was not observed with
siRNA E7 until 96 h or more after transfection. As a ﬁnal
proof of speciﬁcity, we mutated one of the E6AP-speciﬁc
siRNAs (E5), altering the base at two consecutive positions
(E5mut; Figure 5C, bottom). Compared with the wild-type E5
siRNA, transfection of E5mut resulted in neither knockdown
of E6AP or restoration of pRb abundance (Figure 5C;
compare lanes 5 and 6). Consistent with these results,
overexpression of both E6AP and NS5B in Huh-7 cells
enhanced the downregulation of pRb observed previously
with ectopic expression of NS5B alone [8] (unpublished data).
NS5B and pRb Form a Complex with E6AP
A hallmark of E6AP and other HECT domain ligases is
their ability to form a physical complex with the molecule
undergoing ubiquitination. Since the results described above
Figure 5. siRNA Knockdown of E6AP Restores pRb Abundance in HCV
Replicon Cells
(A) siRNA pools specific for the E3 ubiquitin ligases E6AP, MDM2, and
NEDD4, and control siRNAs C1 and C2 were transfected into cured 2–3c
cells (lanes 1–5) and 2–3 replicon cells (lanes 6–10) using a liposome-
mediated procedure. Cell extracts were prepared 72 h later, separated by
SDS-PAGE, and immunoblotted using antibodies to pRb and each of the
target E3 ligases. While the each specific siRNA pool effectively reduced
the abundance of its E3 ligase target, only the E6AP pool caused a
reproducible restoration of pRb abundance in the 2–3 cells.
(B) Effect of E6AP knockdown on pRb abundance using each of the four
different E6AP-specific siRNAs (E5, E6, E7, and E8) comprising the siRNA
pool tested in (A). C1 and C2 are control siRNAs. Lysates were prepared
120 h following transfection.
(C) Transfection of a mutated E6AP siRNA (E5mut) fails to induce
restoration of pRb abundance in 2–3 replicon cells. Nucleotide
sequences of the E5 and E5mut siRNAs are shown at the bottom of
the panel, with the two base substitutions underlined.
doi:10.1371/journal.ppat.0030139.g005
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ubiquitination of pRb, we sought evidence for an interaction
between E6AP, pRb, and NS5B.
We immunoprecipated pRb present in 2–3 cell extracts
using antibody to pRb, and demonstrated that the precipitate
contained detectable E6AP (Figure 6A, lane 6). In contrast,
similarly prepared precipitates from the cured 2–3c cells did
not contain appreciable amounts of E6AP (Figure 6A, lane 5),
nor did precipitates generated from extracts of the 2–3
replicon cells using antibodies to MDM2 or Flag (Figure 6A,
lanes 4 and 8). These results suggest that HCV induces the
formation of a complex involving pRb and E6AP. As we had
previously shown that NS5B interacts with pRb and targets it
for degradation [8], we considered it likely that NS5B was
responsible for the E6AP–pRb complex observed in lysates of
the replicon cells. We conﬁrmed the interaction of NS5B with
pRb by demonstrating the coimmunoprecipitation of NS5B
with pRb in lysates of 2–3 cells (Figure 6B, lane 6). For reasons
that remain unclear, the amount of NS5B present in the pRb
precipitates was markedly reduced when the replicon cells
were treated with epoxomicin prior to preparation of the
extracts (Figure 6B; compare lanes 5 and 6). The overall
abundance of NS5B was also reduced by epoxomicin treat-
ment (Figure 6B; compare lanes 1 versus 2, and Figure 3A and
3B), possibly reﬂecting nonspeciﬁc cellular toxicity and a
related reduction in viral RNA replication.
To demonstrate that the formation of the pRb–E6AP
complex was dependent upon NS5B and not other HCV
proteins expressed by the replicon RNA, we transfected
normal Huh-7 cells with vectors expressing various non-
structural HCV proteins, as shown in Figure 4C. Extracts
prepared from these transfected cells were precipitated with
antibody to pRb, then immunoblotted using antibody to
E6AP. Only expression of wild-type NS5B resulted in the
formation of a complex between pRb and E6AP (Figure 6C,
lane 5). Importantly, this was not observed in cells expressing
an NS5B mutant, D318N/D319N, that fails to bind pRb [8]
(Figure 6C; compare lanes 5 and 6), or in cells ectopically
expressing other nonstructural proteins of the virus: NS3-4A,
NS4B, and NS5A. Taken together, the data shown in Figure 6
indicate that NS5B forms a complex with pRb and E6AP.
Consistent with the results of the siRNA knockdown experi-
ments described above, these data provide strong support for
a role for E6AP in the NS5B-dependent degradation of pRb.
A Dominant-Negative E6AP Mutant Restores pRb
Abundance in Replicon Cells
To determine whether E6AP in fact functions as an E3
ligase for pRb, we assessed the ability of recombinant E6AP to
direct the ubiquitination of pRb in a reconstituted in vitro
ubiquitination reaction using recombinant E1 and E2
proteins. However, these experiments failed to demonstrate
ubiquitination of pRb by E6AP, either in the presence or
absence of NS5B (Figure S3). These results suggest that E6AP
may not be responsible for the NS5B-dependent ubiquitina-
tion of pRb, or that this process requires another cellular or
viral protein partner that was not included in the recon-
stituted in vitro ubiquitination reaction. To distinguish
between these possibilities, we transfected the 2–3 replicon
cells with vectors expressing either wild-type E6AP or a
dominant-negative E6AP protein, E6AP-C840A, that contains
a single amino acid substitution within the C-terminal HECT
Figure 6. NS5B-Dependent Interaction between E6AP and pRb
(A) Endogenous pRb interacts with E6AP in 2–3 replicon cells. Lysates
from 2–3 and 2–3c cells were immunoprecipitated with anti-Flag
(control), anti-pRb, or anti-MDM2 monoclonal antibody, followed by
immunoblotting with anti-pRb and anti-E6AP. All monoclonal antibodies
were derived from the same isotype, IgG1. Ig heavy chain (HC) and
nonspecific bands served as loading controls for the pRb and E6AP
immunoblots, respectively.
(B) Endogenous pRb interacts with NS5B in 2–3 replicon cells in an EPX-
sensitive fashion. 2–3 and 2–3c cells were cultured in the presence or
absence of EPX prior to preparation of lysates. Lysates were immuno-
precipitated with monoclonal anti-pRb antibody, followed by immuno-
blotting with anti-pRb and anti-NS5B antibodies. Note that EPX
treatment reduces the apparent interaction between pRb and NS5B.
(C) Ectopic expression of wild-type NS5B induces interaction between
E6AP and pRb in normal Huh-7 cells. Cells were transfected with vectors
expressing Flag-tagged NS3-4A, NS4B, NS5A, NS5B, and a mutant NS5B,
D318N/D319N, that does not bind pRb [8], and cultured in the presence
of MG115. Cell extracts were immunoprecipitated with anti-pRb
antibody, followed by immunoblotting with anti-pRb and anti-E6AP
antibodies (top panels). The bottom panels show immunoblots of the
cell extracts with the same antibodies.
doi:10.1371/journal.ppat.0030139.g006
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HCV-Induced Degradation of pRbdomain, ablating its E3 ligase activity [35]. Quantitation of
immunoblots from three independent experiments demon-
strated that the overexpression of E6AP-C840A resulted in a
reproducible increase in the abundance of pRb in the 2–3
replicon cells (Figure 7A [compare lanes 4 versus 6] and 7B).
This increase in pRb abundance was clearly apparent in
immunoblots of serial 2-fold dilutions of the cell lysates
(Figure 7C). In contrast, overexpression of wild-type E6AP
caused either no change or a slight increase in pRb
abundance in 2–3 cells, and did not appreciably alter pRb
expression in the cured 2–3c cells (Figure 7A). These results
provide additional evidence that E6AP is required for NS5B-
dependent ubiquitination of pRb, and are consistent with the
effects of siRNA knockdown of E6AP (Figure 5) and the
presence of an NS5B–E6AP–pRb complex in lysates of the
replicon cells (Figure 6). We conclude that E6AP is the E3
ligase responsible for NS5B-dependent ubiquitination of pRb
in vivo.
Discussion
We have shown here that pRb is ubiquitinated and
degraded in a proteasome-dependent fashion in cultured
human hepatoma cells infected with HCV. These observa-
tions enhance the biological relevance of prior studies
showing that pRb is downregulated by the HCV polymerase
protein, NS5B, expressed by autonomously replicating RNA
replicons [8]. In showing that the cellular E6AP and viral
NS5B proteins form a complex that regulates pRb abun-
dance, we have also provided an enhanced mechanistic
understanding of this process.
E6AP was identiﬁed originally as a ubiquitin ligase that
downregulates p53 in cells expressing the HPV E6 protein
[28,36]. The E6–E6AP complex targets additional proteins for
ubiquitination, including a set of PDZ domain proteins
[37,38] and NFX1–91, a repressor of the hTERT promoter
[39]. Interestingly, E6AP has also been shown recently to
ubiquitinate and regulate the stability of the HCV core
protein [32]. The partial restoration of pRb abundance we
observed in the 2–3 replicon cells following either siRNA
knockdown of E6AP (Figure 5) or overexpression of a
dominant-negative E6AP mutant (E6AP-C840A; Figure 7)
provides strong evidence that the ubiquitin ligase activity of
E6AP is required for HCV regulation of pRb. Importantly,
neither E6AP knockdown nor E6AP-C840A expression
altered the abundance of pRb in the clonally related 2–3c
cells that had been cured of the HCV replicon by prior
treatment with interferon. We also found that the ability of
NS5B to form a complex with E6AP is dependent upon the
NS5B LH
314–318 domain [8] that mediates the interaction of
NS5B with pRb (Figure 6C; compare lanes 5 and 6). These
data thus lead us to propose a model in which NS5B interacts
with hypophosphorylated pRb within the cytoplasm and
recruits E6AP to the complex, thereby inducing the ubiquiti-
nation and subsequent degradation of pRb via the protea-
some. Such a model is consistent with the cytoplasmic
redistribution of pRb, as well as the colocalization of pRb
and viral nonstructural proteins (speciﬁcally NS5A) that we
observed by confocal microscopy in cells infected with HCV
in vitro (Figure 2A and 2B).
Several possible explanations exist for the inability of E6AP
to ubiquitinate pRb in an NS5B-dependent fashion in
reconstituted in vitro reactions (Figure S3). First, it may be
that additional cellular or viral proteins are required for
ubiquitination. Strong evidence exists for functionally im-
portant interactions between the NS5B polymerase and
several cellular proteins other than pRb, including vesicle-
associated membrane-associated proteins A and B (VAP-A
and VAP-B), cyclophilin B (CypB), and protein kinase C–
related kinase 2 (PRK2), which putatively regulates NS5B by
phosphorylation, as well as hPLIC-1, mentioned above [27,40–
43]. The deletion of a 21–amino acid C-terminal hydrophobic
domain in the NS5B used in our assays (which is required for
its solubility) [44,45], could also have affected the in vitro
assays, potentially compromising the ability of the polymer-
ase to undergo the conformational changes required for
efﬁcient interaction of the LH
314–318 domain with pRb [8].
This domain overlaps the Gly-Asp-Asp motif within the active
site of the NS5B polymerase, and is sequestered within the
interior of the protein in its fully folded form [46].
Prior studies indicate that pRb abundance is regulated by
several different mechanisms, reﬂecting in turn its role as a
master regulator of the cell cycle. The E3 ligase MDM2 plays a
prominent role in its regulation in the absence of HCV
infection [23,24]. While we observed a variable increase in
pRb abundance following siRNA knockdown of MDM2 in the
2–3 replicon cells (Figure 5A; compare lanes 6–7 and 10), this
effect was typically less than that observed with E6AP
Figure 7. HCV-Induced Degradation of pRb Is Dependent upon the
Ubiquitin Ligase Activity of E6AP
(A) Immunoblot analysis showing that ectopic expression of a dominant-
negative E6AP mutant (E6AP-C840A) partially restores pRb abundance in
HCV replicon cells. 2–3 and cured 2–3c cells were transfected with
vectors expressing wild-type E6AP and E6AP-C840A, which contains a
mutation within the catalytic site of the ubiquitin ligase and acts as
dominant-negative [35]. Cell extracts were immunoblotted with anti-pRb
and anti-E6AP antibodies. Actin was used as a loading control.
(B) Mean 6 standard deviation of values for abundance of pRb in cells
transfected with wild-type and mutant E6AP expression vectors obtained
in three replicate experiments carried out as shown in (A), relative to
abundance in cells transfected with an empty vector.
(C) Quantitative pRb immunoblots of serial 2-fold dilutions of lysates of
2–3 cells transfected with expression vectors for wt E6AP, E6AP-C840A,
or empty vector.
doi:10.1371/journal.ppat.0030139.g007
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HCV-Induced Degradation of pRbknockdown (compare lanes 9 and 10). Moreover, in contrast
to E6AP, we were not able to demonstrate an interaction
between NS5B and MDM2 (unpublished data). pRb is also
targeted for proteasome-mediated degradation by the E7
oncoprotein expressed by high-risk HPVs [47]. Although
recognized for many years, the mechanism underlying its
regulation by E7 has remained for the most part obscure.
However, an active cullin 2 ubiquitin ligase complex has been
reported recently to be associated with the HPV type 16 E7
protein, and has been implicated in this process [48]. The
Epstein-Barr virus latent antigen 3C mediates degradation of
pRb by recruiting the SCF
Skp2 ubiquitin ligase [49]. Thus, the
steady-state abundance of pRb appears to be regulated
through the actions of three distinct E3 ligases: by MDM2 in
normal cells, by SCF
Skp2 in Epstein-Barr virus–infected B
cells, and (as our data suggest) by E6AP in HCV-infected
hepatocytes. The human cytomegalovirus pp71 protein also
promotes the degradation of pRb and its associated family
proteins, but does so in a proteasome-dependent, ubiquitin-
independent manner [50]. In addition, gankyrin, an onco-
genic ankyrin-repeat protein that is overexpressed in most
HCCs, associates with pRb and reduces its stability [51].
While the abundance of pRb may be regulated through a
diversity of mechanisms, its activity in controlling E2F
transcription factors is largely regulated by phosphorylation
[14]. The sequential phosphorylation of pRb plays a pivotal
role in the G1/S-phase transition. In its hypophosphorylated
state, pRb sequesters and represses the E2F family of
transcription factors [13]. Mitogenic growth factors induce
phosphorylation of pRb by activation of cyclin D–Cdk4/6 and
cyclin E/Cdk2 complexes [52]. This results in release of E2F
proteins from pRb, and promotes transcriptional activation
of genes required for S-phase and DNA replication. It also
appears to promote the nuclear export of pRb, at least in
some cell types [21]. Conversely, growth-inhibitory signals
reduce cyclin levels or induce Cdk inhibitors, resulting in
decreased cyclin/Cdk activity, hypophosphorylation of pRb,
and, subsequently, repression of E2F-target genes. Impor-
tantly, some ubiquitin ligases are known to catalyze ubiquiti-
nation in a phosphorylation-dependent manner. For
example, ubiquitination of p27
Kip1 is triggered by phosphor-
ylation on Thr187 by Cdk2–cyclin E/A kinase complexes
[53,54]. Phosphorylated p27
Kip1 is then recognized by
SCF
Skp2, which polyubiquitinates p27
Kip1, targeting it for
degradation by the proteasome. At present, we have no direct
evidence that phosphorylation inﬂuences the ubiquitination
and degradation of pRb. However, the relatively low
abundance of cytoplasmic phospho-pRb in epoxomicin-
treated hepatoma cells infected with HCV (Figure 2D, frame
vi) suggests that NS5B may interact preferentially with
hypophosphorylated pRb. pRb is also subject to acetylation
and sumoylation, both of which regulate pRb function within
the cell cycle [55,56], and could also inﬂuence how pRb is
ubiquitinated. The effect of such modiﬁcations on the
regulation of pRb by HCV will require further study.
Since the ectopic expression of NS5B stimulates the activity
of E2F-responsive promoters, S-phase entry, and cellular
proliferation [8], it seems likely that HCV regulation of pRb
abundance may enhance the proliferative rate of infected
hepatocytes. This virus–host interaction may have evolved
because it favors viral RNA replication, which is known to be
stimulated in proliferating cells in vitro [57,58]. A more
important question, however, is whether the NS5B-mediated
degradation of pRb could contribute to the development of
HCC in patients with chronic HCV infection.
While the manner in which the expression of E7 by high-
risk papillomaviruses contributes to cervical cancer [59] may
hold some analogies for HCV, it is likely that HCV regulation
of pRb promotes the development of liver cancer in a more
indirect fashion. In addition to its role in controlling the G1-
to S-phase transition, pRb regulates mitotic checkpoints that
are critical controls in prevention of cancer, as they allow
cells to repair chromosomal damage before DNA replication
or cell division. The risk of oxidative chromosomal DNA
damage is likely to be enhanced due to inﬂammation within
the liver during chronic hepatitis C, increasing the impor-
tance of these mitotic checkpoints. However, to be fully
functional, these checkpoints require competent p53 and
pRb pathways [60,61]. Expression of the E6 and E7 proteins
from high-risk HPVs can override DNA damage-induced G1
arrest [62], while E6 proteins from high-risk HPVs are also
able to compromise the G2/M DNA damage checkpoint [63].
We have shown previously that NS5B-mediated degradation
of pRb results in an upregulation of the activity of the E2F-
responsive Mad2 promoter [8]. Importantly, deregulation of
Mad2, an essential component of the mitotic spindle
checkpoint, leads to aneuploidy and an increased risk of
tumors, including hepatomas, in mice [64,65]. Thus, while it
remains to be proven that HCV infection disrupts mitotic
checkpoints through downregulation of pRb, it is a reason-
able hypothesis. By downregulating pRb abundance, HCV
infection would both stimulate hepatocellular proliferation
within a local environment rich in reactive oxygen species
and also impair the ability of the cell to respond appropri-
ately to DNA damage. The net result would be increased
chromosomal instability. Such a hypothesis is consistent with
the diversity of chromosomal abnormalities found in HCC, as
well as the typically lengthy period spanning the onset of
HCV infection to the development of HCC, and should
provide a useful framework for future investigations.
Materials and Methods
Cells. Human hepatoma cells Huh-7 and Huh-7.5 [66] were grown
in Dulbecco modiﬁed Eagle medium (Cellgro, http://www.cellgro.com/)
supplemented with 10% (v/v) heat-inactivated fetal bovine serum, 100
U/ml penicillin G, and 100 lg/ml streptomycin, at 37 8Ci na
humidiﬁed atmosphere with 5% (v/v) CO2. The NNeo/C-5B 2–3,
Huh-7–derived cell line containing autonomously replicating, ge-
nome-length, dicistronic, selectable HCV RNAs derived with the
genotype 1b HCV-N strain were cultured with 500 lg/ml G418, as
described previously (Cellgro) [22]. Its companion, interferon-cured
progeny cell line 2–3c, was generated and maintained as described
previously, and contains no HCV RNA [58].
Virus. Cell culture–infectious genotype 1a H77S and genotype 2
JFH1 viruses were harvested from the supernatant ﬂuids of cultures
of RNA transfected Huh-7.5 cells, and stored at  80 8C until use
[16,20]. For experiments with JFH1 virus, cells were inoculated at a
multiplicity of infection (MOI) of 1–2, and virus was allowed to
adsorb to cells for 6–12 h at 37 8C prior to replacement of media. pRb
abundance and cellular localization was ascertained by immunoblot-
ting and confocal microscopy 48–120 h after infection. H77S
infections were carried out at an MOI of ;0.01 due to the lower
efﬁciency of virus production, and cells were examined by confocal
microscopy only.
Plasmids. pCMV6-hE6AP, containing full-length cDNA of human
E6AP cloned into the mammalian expression vector pCMV6, was
purchased from OriGene. A dominant-negative mutant, E6AP
C840A, was generated by PCR mutagenesis using pCMV6-hE6AP as
a template with the primers 59-GCC TTT AAT GTG CTT TTA CTT
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Human ubiquitin B precursor cDNA was purchased from OriGene
(http://www.origene.com/), and cDNA representing the mature ubiq-
uitin was subcloned into the pGEM-T Easy cloning vector (Promega,
http://www.promega.com/) after ampliﬁcation by PCR using the
primers 59-CCG GAA TTC ATG CAG ATC TTC GTG AAA ACC
CTT AC-39 and 59-GCT CTA GAT TAA CCA CCT CTC AGA CGC
AGG ACC-39 to generate pTM-047. After conﬁrming the sequence of
both strands of the insert, pTM-047 was digested with EcoRI and
XbaI, and the 0.25-kb fragment containing the ubiquitin open
reading frame was subcloned into pcDNA3.1/Zeo/IRES-3xFLAG to
generate a 3xFLAG-tagged ubiquitin expression vector. pEGFP-C1,
pORF9-hRB1, pCMV-tag4-NS3/4A, pCMV-tag4-NS4B, pCMV-tag4-
NS5A, pCMV-tag4-NS5B wt, and pCMV-tag4-NS5B D318N/D319N
were constructed as described previously [8].
Proteasome inhibitors. Lactacystin, MG115, and epoxomicin (all
from Calbiochem, http://www.emdbiosciences.com/) were prepared as
solutions in DMSO. For treatment of replicon cells, 2–3 replicon and
cured 2–3c cells were seeded into 6-well plates and grown to 50%
conﬂuence. Inhibitors were added to the culture media at the
indicated concentrations, and cells were incubated for 10–12 h
(lactacystin or MG115) or 20 h (epoxomicin), followed by preparation
of cell extracts for immunoblots. For epoxomicin treatment of JFH1
virus–infected cells, the inhibitor was added 20 h prior to lysis of cells
and preparation of cell extracts.
RNA interference. siRNA oligonucleotide SMARTpools, each
containing four siRNA oligonucleotides speciﬁc for human MDM2
(M-003279–02), E6AP/UBE3A (M-005137–00), and NEDD4 (M-
007178–01), and individual E6AP/UBE3A siRNAs, were purchased
from Dharmacon (http://www.dharmacon.com/). Negative control
siRNAs (4611 and 4613) were from Ambion (http://www.ambion.
com/). For knockdown experiments, 2–3 replicon and cured 2–3c cells
were grown to 30% conﬂuence in 6-well plates, and transiently
transfected with 80 nM of siRNAs using Lipofectamine 2000
(Invitrogen, http://www.invitrogen.com/) according to the manufac-
turer’s instructions. Protein extracts were prepared for further
analysis 72–120 h after transfection.
Transfection. Cells were seeded into 6-well plates 24 h before
transfection and grown to 50% conﬂuence. Before transfection, the
culture medium was replaced with fresh medium without antibiotics.
For overexpression of E6AP or E6AP C840A, 2–3 and 2–3c cells were
transiently transfected with 4 lg of pCMV6 (empty vector), pCMV6-
hE6AP, or pCMV6-hE6AP-C840A, along with 0.25 lg of pEGFP-C1
(Promega), using FuGENE 6 reagents (Roche Diagnostics, http://www.
roche.com/). Protein extracts were prepared for immunoblots at 48 h
after transfection.
Immunoblots. Cells were washed three times with chilled PBS, and
incubated in chilled lysis buffer (20 mM Tris-HCl [pH7.5], 150 mM
NaCl, 10 mM EDTA-2Na, 1% [v/v] Nonidet P-40, 10% [v/v] glycerol,
and 2 mM DTT) supplemented with 1 mM PMSF and 2 lg/ml
aprotinin, or complete protease inhibitor cocktail (Roche), for 30 min
at 4 8C. Cell debris was pelleted by centrifugation at 13,000g for 30
min at 4 8C, and supernatants were used as soluble fractions. Protein
concentrations were determined by the modiﬁed Bradford assay with
BSA as a standard (Bio-Rad, http://www.bio-rad.com/). SDS-PAGE and
subsequent immunoblotting were done as described previously [8],
using mouse monoclonal antibodies against b-actin (AC-15; Sigma,
http://www.sigmaaldrich.com/), GAPDH (glyceraldehyde-3-phosphate
dehydrogenase; Ambion), Flag tag (M2; Sigma), MDM2 (SMP14; Santa
Cruz Biotechnology, http://www.scbt.com/), pRb (G3–245; BD Bio-
sciences, http://www.bdbioscences.com/), and ubiquitin (P4D1; Santa
Cruz Biotechnology), and rabbit polyclonal antibodies against
phospho-pRb 807/811 (Cell Signaling Technology, http://www.
cellsignal.com/), E6AP (sc-25509; Santa Cruz Biotechnology), NEDD4
(sc-25508; Santa Cruz Biotechnology), and NS5B (A266–1; ViroGen,
http://www.virogen.com/; or provided as a generous gift by Dr. Craig
E. Cameron, Pennsylvania State University, State College, Pennsylva-
nia, United States). Membranes were probed with appropriate
secondary antibodies conjugated with horseradish peroxidase,
visualized by ECL reagents (Amersham Pharmacia Biosciences,
http://www.amersham.com/), and exposed to x-ray ﬁlms.
Indirect ﬂuorescence microscopy. Huh-7 2–3 and 2–3c cells were
seeded into 8-well Labtek chamber slides and grown until 50%–60%
conﬂuent, with or without the addition of 20 lM of MG115. After
washing twice with PBS, the cells were ﬁxed in methanol–acetone (1:1
[vol/vol]) for 10 min at  20 8C, air-dried for 60 min at room
temperature, washed twice with PBS, and incubated with blocking
buffer (1% BSA in PBS) overnight at 4 8C. pRb was visualized by
staining with mouse monoclonal antibody G3–245. After washing
three times with PBS, slides were further incubated with a goat anti-
mouse Ig secondary antibody conjugated with FITC for 1 h at room
temperature. Slides were then washed three times with PBS,
counterstained with diamidino-2-phenylindole 2HCl (DAPI),
mounted in Vectashield mounting medium (Vector Laboratories,
http://www.vectorlabs.com/), and examined with a Zeiss AxioPlan2
ﬂuorescence microscope (http://www.zeiss.com/).
Confocal imaging. Huh-7 2–3 and 2–3c cells or JFH1-infected Huh-
7.5 cells were cultured in Labtek chamber slides (http://www.labtek.
net/) and ﬁxed with 4% paraformaldehyde in PBS for 30 min. Cells
were permeabilized with Triton X-100 (0.2%) for 15 min and blocked
with 10% normal goat serum at room temperature for 1 h. Cells were
then incubated with the appropriate dilutions of primary antibodies
for 1 h followed by secondary antibodies for 1 h at room temperature.
HCV antigen was visualized with rabbit polyclonal antibody to NS5A
(a generous gift from Dr. Craig E. Cameron) followed by Alexa 594
secondary antibody conjugate, or with human polyclonal antibody
and an FITC-labeled anti-human Ig secondary antibody; pRb was
visualized with visualized by staining with mouse monoclonal anti-
body G3–245 (BD Biosciences), and phospho-pRb by rabbit poly-
clonal antibody against phospho-pRb 807/811 (Cell Signaling
Technology) followed by secondary antibodies: goat anti-mouse Ig
conjugated to FITC or goat anti-rabbit Ig conjugated to Alexa 594.
Slides were washed and counterstained with DAPI, and mounted in
Vectashield mounting medium, then sealed and examined with a
Zeiss LSM 510 laser scanning confocal microscope within the
Infectious Disease and Toxicology Optical Imaging Core at the
University of Texas Medical Branch.
Pulse-chase analysis. Pulse-chase labeling of endogenous pRb
protein was done as described previously [8].
Coimmunoprecipitation analysis. For analysis of the interaction
between pRb and E6AP in normal Huh-7 cells, cells were grown to
50% conﬂuence in 10-cm dishes and transfected with 5 lg of pCMV-
tag4, pCMV-tag4-NS3/4A, pCMV-tag4-NS4B, pCMV-tag4-NS5A,
pCMV-tag4-NS5B wt, and pCMV-tag4-NS5B D318N/D319N. At 48 h
after transfection, 20 lM of MG115 was added to the transfected cells
for 10 h. Cells were lysed in 1 ml of IP lysis buffer (20 mM Tris-HCl
[pH7.5], 150 mM NaCl, 10 mM EDTA-2Na, 1% [v/v] NP-40, 10% [v/v]
glycerol, 1 mM PMSF, and 2 lg/ml aprotinin), and extracts were
prepared as described above. IP was performed with 500 lgo f
extracts using anti-pRb monoclonal antibodies, as described pre-
viously, and immunoprecipitated proteins were analyzed by immu-
noblot [8]. For analysis of the interaction between pRb and E6AP in
HCV replicon cells, 2–3 replicon and 2–3c cured cells were lysed in IP
lysis buffer, and soluble extracts were prepared. IP was performed
with 500 lg of extracts using 1 lg of anti-FLAG (M2; Sigma), anti-pRb
(G3–245; BD Biosciences), or anti-MDM2 (SMP14; Santa Cruz
Biotechnology) monoclonal antibody, and immunoprecipitated pro-
teins were analyzed by immunoblot.
For analysis of the interaction between NS5B and ubiquitinated
pRb, NNeo/C-5B 2–3 and 2–3c cured cells were transfected with
3xFLAG-tagged ubiquitin expression vector, and treated with DMSO
or 20 lM MG115 for the last 10 h. At 48 h after transfection, cells were
lysed in IP lysis buffer, and soluble extracts were prepared. IP was
carried out using 500 lg of extracts and anti-FLAG monoclonal
antibody, and immunoprecipitated proteins were analyzed by
immunoblot.
Cellular ubiquitination assays. For detection of ubiquitinated pRb,
2–3 replicon cells and 2–3c cured cells were cultured to 50%
conﬂuence in 10-cm dishes and transfected with 5 lg of 3xFLAG-
tagged ubiquitin expression vector. At 48 h after transfection, cells
were treated with DMSO, 10 lM of lactacystin, or 20 lM of MG115 for
10 h, and then lysed in IP lysis buffer supplemented with 1 mM NaF, 1
mM Na3VO4, 4 mM N-ethylmaleimide, and 6 nM ubiquitin aldehyde
(ubiquitination buffer), and soluble extracts were prepared. A total of
500 lg of extracts were used for IP with anti-FLAG monoclonal
antibodies, and immunoblots were carried out with anti-pRb or
antiubiquitin monoclonal antibodies.
For detection of NS5B-dependent ubiquitination of pRb, normal
Huh-7 cells were cultured to 50% conﬂuence in 6-well plates, and
transfected with 2 lg pCMV-tag4, pCMV-tag4-NS3/4A, pCMV-tag4-
NS4B, pCMV-tag4-NS5A, pCMV-tag4-NS5B wt, and pCMV-tag4-
NS5B D318N/D319N. At 48 h after transfection, 20 lM of MG115
was added to the transfected cells for 10 h. Cells were lysed in
ubiquitination buffer, and soluble extracts were prepared. IP was
carried out using anti-pRb monoclonal antibodies, followed by
immunoblotting with monoclonal antiubiquitin antibody.
In vitro ubiquitination assays. Reconstituted, in vitro ubiquitina-
tion reactions were carried out using puriﬁed recombinant pRb
(Abcam, http://www.abcam.com/), recombinant NS5B protein with a
21–amino acid C-terminal deletion (Replizyme, http://www.replizyme.
PLoS Pathogens | www.plospathogens.org September 2007 | Volume 3 | Issue 9 | e139 1345
HCV-Induced Degradation of pRbcom/), and recombinant E6AP produced in baculovirus, essentially as
described [35].
Supporting Information
Figure S1. Quantitative Immunoblot for pRb in Lysates of Huh-7
Cells Prepared 120 h Following Mock Infection or Infection with
JFH1 Virus
Two-fold dilutions of lysates from mock-infected or JFH1-infected
cells were blotted and probed for pRb, NS5B, and GAPDH (see Figure
1B). Densitometry of the pRb and GAPDH bands detected in the 1:2
and 1:4 lysate dilutions suggested a 63%–70% reduction in pRb
abundance in the infected cells versus uninfected cells.
Found at doi:10.1371/journal.ppat.0030139.sg001 (926 KB TIF).
Figure S2. Inhibition of Proteasomes with MG115 Partially Restores
pRb Abundance in NNeo-C5B/2–3 HCV Replicon Cells, but Has No
Effect on pRb Abundance in Interferon-Cured, HCV-Negative 2–3c
Cells
2–3 and 2–3c cells were treated with 0, 10, or 20 lM MG115 for 8 h,
followed by lysis and immunoblot analysis of pRb and NS5B. GAPDH
was used as a loading control.
Found at doi:10.1371/journal.ppat.0030139.sg002 (725 KB TIF).
Figure S3. E6AP Does Not Mediate NS5B-Dependent Ubiquitination
of pRb In Vitro
The reconstituted cell-free reaction included puriﬁed recombinant
pRb (and puriﬁed p53 as a control), E1, E2, and E6AP proteins, with
and without puriﬁed, recombinant NS5B (with a 21–amino acid C-
terminal deletion to improve its solubility) or HPV E6 proteins.
Results conﬁrmed the ubiquitin ligase activity of the recombinant
E6AP protein by demonstrating the production of high-molecular-
mass ubiquitinated protein (‘‘Ubi-X’’) in reactions containing both
the HPV E6 protein and p53 as a substrate (compare lanes 5 and 6).
While a small amount of ubiquitinated pRb was generated in reaction
mixes containing E1, E2, and E6AP (compare lanes 1 and 2), this was
not increased by the addition of NS5B (lane 3). The data shown are
representative of three independent experiments carried out under
similar conditions. Similar experiments, using as substrate pRb that
had been translated in vitro in rabbit reticulocyte lysates, failed to
demonstrate NS5B-dependent ubiquitination of pRb (unpublished
data).
Found at doi:10.1371/journal.ppat.0030139.sg003 (1.3 MB TIF).
Accession Numbers
The Entrez Protein (http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?db¼Protein) accession numbers for the proteins discussed in
this study are as follows: pRb (NP_000312), E6AP (NP_061828),
MDM2 (NP_002383), NEDD4 (NP_006145), ubiquitin (NP_061828),
HCV-N full-length polyprotein (AAD44719), and JFH1 full-length
polyprotein (BAB32872).
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